^
    Back
    Association details:
    Biomarker:SLC7A5 overexpression
    Cancer:Biliary Tract Cancer
    Drug:nanvuranlat (JPH203) (SLC7A5 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    Subgroup analysis of double-blind, placebo-controlled Ph. 2 study of nanvuranlat in treatment of pre-treated, advanced, refractory biliary tract cancer (BTC): Patients with high LAT1 expression and response to nanvuranlat.

    Published date:
    05/25/2023
    Excerpt:
    Nanvuranlat met its primary endpoint (FAS by the blinded independent central review (BICR)), demonstrating a statistically significant improvement in PFS by BICR in comparison with the placebo group….This subgroup analysis indicates that the efficacy of nanvuranlat in PFS and OS is enhanced in BTC patients with high LAT1 expression, when compared with placebo.
    DOI:
    10.1200/JCO.2023.41.16_suppl.4011